Literature DB >> 22480231

Treatment of adult soft tissue sarcoma: old concepts, new insights, and potential for drug discovery.

Jeanny B Aragon-Ching1, Robert G Maki.   

Abstract

Soft tissue sarcomas are a heterogeneous group of mesenchymal tumors that vary in their behavior as well as treatment. Certain histologic subtypes predict for response to particular chemotherapy drugs, while molecular genetics not only increasingly aid in the diagnosis but also has an emerging role in the identification of potential targets for drug therapy. Herein we review the varying soft tissue sarcoma subtypes, their staging, and management. Furthermore, improvement in the understanding of novel mechanisms involved in soft tissue sarcomas lends insight into the compelling role of the use of newer agents with promising results that are discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22480231     DOI: 10.3109/07357907.2012.658936

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  5 in total

1.  Expression of high mobility group box 1 protein predicts a poorer prognosis for patients with osteosarcoma.

Authors:  Jiliang He; Peng Zhang; Qinghu Li; Dongsheng Zhou; Ping Liu
Journal:  Oncol Lett       Date:  2015-11-10       Impact factor: 2.967

2.  Potential benefit of hormonal therapy for non-uterine soft tissue sarcoma (STS) - a case report and literature review.

Authors:  Li Li; Isaiah P Schuster; Robin Jacob; Kenneth H Hupart; Vladimir Gotlieb
Journal:  Springerplus       Date:  2013-10-17

3.  Histologic variability and diverse oncologic outcomes of prostate sarcomas.

Authors:  Mooyoung Sohn; Taekmin Kwon; In Gab Jeong; Sungwoo Hong; Dalsan You; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim
Journal:  Korean J Urol       Date:  2014-11-28

4.  Polyphyllin I suppresses human osteosarcoma growth by inactivation of Wnt/β-catenin pathway in vitro and in vivo.

Authors:  Junli Chang; Yimian Li; Xianyang Wang; Shaopu Hu; Hongshen Wang; Qi Shi; Yongjun Wang; Yanping Yang
Journal:  Sci Rep       Date:  2017-08-08       Impact factor: 4.379

5.  Bone and Soft Tissue Sarcoma.

Authors:  Antonio Ruggiero
Journal:  Cancers (Basel)       Date:  2020-09-12       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.